Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PH-1

Financiado

Cerrado

NEW DRUGS FOR THE TREATMENT OF PRIMARY HIPEROXALURIA

Primary hiperoxaluria (PH-1) is a human genetic disease consisting on a deficiency of alanine-glyoxylateaminotransferase (AGT) activity in hepatocytes. This enzyme metabolizes glyoxylate and a lack of its activity leads to an exce... ver más

02/11/2013

UGR

45K€

Presupuesto del proyecto: 45K€

Líder del proyecto

UNIVERSIDAD DE GRANADA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 5514

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-11-02 No tenemos la información de la convocatoria

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UGR

0.00€ | Lider

Proyectos interesantes

RTI2018-098560-B-C21

Medical Technol...

Pharmaceutical...

133K€ Cerrado

RTI2018-098560-B-C22

Medical Technol...

Biotechnology

85K€ Cerrado

SAF2015-69796-C2-1-R

Medical Technol...

Data Science

157K€ Cerrado

SAF2014-51991-R

Medical Technol...

Biotechnology

182K€ Cerrado

PTQ-10-04069

Medical Technol...

Medical Devices

45K€ Cerrado

AIPGENE

Medical Technol...

Genetic Enginee...

4M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSIDAD DE GRANADA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 5514

Presupuesto del proyecto 45K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Primary hiperoxaluria (PH-1) is a human genetic disease consisting on a deficiency of alanine-glyoxylateaminotransferase (AGT) activity in hepatocytes. This enzyme metabolizes glyoxylate and a lack of its activity leads to an excessive production of oxalate. Oxalate accumulation damages kidney and liver functions at first and other tissues and organs later. This disease is lethal and no effective pharmacological treatment exists nowadays; renal and hepatic transplants become necessary to preserve the life of the patients. Several mutations on AGT gene, leading to protein misfolding that avoids enzymatic activity, have been described as responsible for this disease. Our objective in this project is to develop an effective treatment for PH-1, based in a strategy of pharmacological stabilization of AGT. This novel approach is the state of the art for protein misfolding, and it is based in the use of pharmacological chaperones to recover protein active conformation. In this Memory we include the design, synthesis and biological evaluation of a series of chaperones for AGT. The synthesis has been designed following a Diversity Oriented Synthesis-like scheme, based on the knowledge of the recently described enzyme active site and it is an application of the skills that the applicant acquired during her postdoctoral stay at Cambridge University (UK) as a Marie Curie IEF-Fellow. The project is a multidisciplinary approach with a synthetic chemical part to be developed at the University of Granada, where the applicant is Assistant Lecturer, and a biological part to be developed during short stays at the University of La Laguna (Canary Islands, PH-1 endemic zone) in collaboration with Prof. Eduardo Salido, a specialist in PH-1. The project deals with a topic of interest in European Research as it faces the treatment of an orphan disease that is endemic in some regions of Europe, and it meets a part of the therapy not fully covered by the pharmaceutical industry

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores